Skip to main content

Posluma

flotufolastat F 18
Used for Diagnosis

Posluma (flotufolastat F 18) is an radiopharmaceutical imaging agent that helps providers see areas of prostate cancer on a specific test known as a prostate-specific membrane antigen – positron emission tomography (PSMA-PET) scan. It’s for people with prostate cancer that might have come back after initial treatment (recurrent) or spread (metastasized) to other parts of the body. It’s given as an infusion through the vein before the PET scan. Side effects include diarrhea, injection site pain, and a rise in blood pressure.

Reviewed by:Last reviewed on December 17, 2023
basics-icon

What is Posluma (flotufolastat F 18)?

What is Posluma (flotufolastat F 18) used for?

How Posluma (flotufolastat F 18) works

Posluma (flotufolastat F 18) is a radiopharmaceutical. It attaches to a particular protein found on the surface of certain cancer cells called prostate-specific membrane antigen (PSMA). Once attached, the radioactive portion of Posluma (flotufolastat F 18) lights up the areas with prostate cancer on a certain type of scan called a PSMA PET scan.

Drug facts

Common BrandsPosluma
Drug ClassRadiopharmaceutical
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
dosage-icon

Posluma (flotufolastat F 18) dosage

Typical dosage for Posluma (flotufolastat F 18)

alternatives-icon

What are alternatives to Posluma (flotufolastat F 18)?

There are a number of medications that your doctor can prescribe in place of Posluma (flotufolastat F 18). Compare a few possible alternatives below.
Posluma (flotufolastat F 18)
Used for:
Used for:

PET scans to find cancer cells in:

Used for:

PET scans to find cancer cells in:

  • Men with treatable prostate cancer that might have spread to other organs
  • Men with a history of prostate cancer that has come back based on high levels of prostate-specific antigen (PSA)

References

Best studies we found

Blue Earth Diagnostics. (2023). Posluma- flotufolastat f-18 injection [package insert]. DailyMed.

Chang, S. S. (2004). Overview of prostate-specific membrane antigen. Reviews in Urology.

Munjal, A., et al. (2023). Radiopharmaceuticals. StatPearls.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.